Description
Breast cancers that express the progesterone receptor (PR) are more likely to respond to anti-estrogen (tamoxifen) treatment. The rabbit monoclonal antibody with a high affinity is the Progesterone Receptor [SP2] antibody clone. According to a study, the SP2 clone’s affinity for the progesterone receptor was significantly higher than that of mouse monoclonals. Research has also demonstrated that the SP2 clone supports ER’s ability to predict survival in cases of human breast cancer.
